Polysaccharide Patents (Class 514/54)
  • Patent number: 11446326
    Abstract: A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose plus galactose molar ratio of greater than or equal to about 1.1, 1.2 or 1.3.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: September 20, 2022
    Assignee: ARC Medical Devices
    Inventors: Christopher Michael Kevin Springate, Sailesh Haresh Daswani
  • Patent number: 11446235
    Abstract: The topical cosmetic compositions and methods of the subject invention can be used to treat and/or prevent a variety of skin conditions, including, for example, age spots, acne, scars, body odor, aging-related conditions (e.g., wrinkles, looseness and dryness), and scalp issues (e.g., dandruff, seborrheic dermatitis and hair loss). In preferred embodiments, the compositions according to the subject invention comprise biological amphiphilic molecules produced by microorganisms.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: September 20, 2022
    Assignee: LOCUS IP COMPANY, LLC
    Inventors: Sean Farmer, Ken Alibek, Sharmistha Mazumder
  • Patent number: 11441131
    Abstract: Heparosan synthase variants having improved expression levels, enhanced thermal stability, and/or reduced reverse glycosylation activity are provided. Methods for making oligosaccharides and polysaccharides, including heparin analogs and heparan sulfate analogs, are also described.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: September 13, 2022
    Assignee: The Regents of the University of California
    Inventors: Xi Chen, Lan Na, Hai Yu, John B. McArthur
  • Patent number: 11432578
    Abstract: A synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2?-fucosyllactose (2?FL), 3?-O-sialyllactose (3?-SL), 6?-O-sialyllactose (6?-SL) either difucosyllactose (DFL) or 3-fucosyllactose (3-FL), preferably DFL, and optionally lactose. Said synthetic composition is useful for: treating or preventing viral and/or bacterial infection in a non-infant human; modulating the microbiota of a non-infant human; and/or improving the cognitive function of a non-infant human and as a pharmaceutical or nutritional composition.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: September 6, 2022
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Louise Kristine Vignæs
  • Patent number: 11433158
    Abstract: An absorbent article comprising a topsheet, a backsheet joined to the topsheet, and an absorbent core positioned intermediate the topsheet and the backsheet and comprising a core absorbent material, in which the core absorbent material comprises superabsorbent polymers with a bio-based content from about 5% to about 100% using ASTM D6866-10, method B and the absorbent article comprises a polyolefin content of at least about 90% by weight, based on a total weight of the absorbent article excluding the core absorbent material.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: September 6, 2022
    Assignee: The Procter & Gamble Company
    Inventors: Paul Thomas Weisman, Eric Patton Weinberger
  • Patent number: 11426424
    Abstract: A method for treatment of vaginal disorders may include: administering topically to a subject in need thereof a therapeutically effective amount of molecular oxygen and hyaluronic acid. The molecular oxygen may be in gaseous form. The vaginal disorders may be selected between vaginal dryness and vulvovaginal atrophy.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: August 30, 2022
    Assignee: CARESS FLOW S.r.l.
    Inventor: Leone Condemi
  • Patent number: 11426427
    Abstract: The invention relates to an isotonic crystalloid aqueous solution of the type containing Na+, K+ and Cl?, and to the use thereof as a vasodilator.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: August 30, 2022
    Inventor: Lara Oller Duque
  • Patent number: 11419886
    Abstract: The present disclosure relates to methods of treating chronic conditions of the eye, such as dry eye disease and blepharitis, as well as to methods for increasing secretion of meibum. This disclosure also relates to formulations suitable for treating chronic conditions of the eye such as dry eye disease and blepharitis.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: August 23, 2022
    Assignee: SIGHT SCIENCES, INC.
    Inventors: Paul Badawi, David Y. Badawi
  • Patent number: 11419889
    Abstract: Oral compositions generally, but not exclusively, used for post dental implants that provide low abrasiveness and improved sanitization and protection of dental implants as well as facilitation of tissue regeneration with better active stability and compatibility as well as synergistic effects are described. The oral compositions include one or more mucus regenerators, one or more antiseptic agents, and one or more orally acceptable carrier actives selected from a group of one or more thickeners, one or more humectants, one or more sweeteners, a preservative, one or more surfactants, a film forming agent, a thixotropic agent, a solubilizing agent, a chelating agent, a coloring agent, an anti-tartar agent, an abrasive, an antioxidant agent, a flavoring agent, and a water vehicle, or mixtures thereof.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: August 23, 2022
    Inventor: Ariel Lenharo
  • Patent number: 11419891
    Abstract: High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60% w/w of the composition has a molecular weight above 100 kDa.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: August 23, 2022
    Assignee: ARC Medical Devices Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun
  • Patent number: 11421047
    Abstract: A packaging system for the storage of an ophthalmic device includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more crosslinked polymeric networks. The one or more crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a first crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan. The aqueous packaging solution has an osmolality of at least about 180 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: August 23, 2022
    Assignee: Bausch & Lomb Incorporated
    Inventors: George L. Grobe, III, Alok Kumar Awasthi, Mark R. Mis, Jennah L. Wolcott, James R. Hauenstein
  • Patent number: 11421044
    Abstract: Several embodiments of NO releasing structures are disclosed. In some embodiments, the structures are covalently modified to store and release nitric oxide. Some embodiments pertain to methods of making and use of these structures. The covalently modified polymer structures may be tailored to release nitric oxide in a controlled manner and are useful for treatment of various medical conditions.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 23, 2022
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Mark H. Schoenfisch, Mona Jasmine R. Ahonen, Lei Yang, Haibao Jin, Evan Scott Feura, Sara Elizabeth Maloney
  • Patent number: 11413303
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: August 16, 2022
    Assignee: GALECTIN THERAPEUTICS, INC.
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Patent number: 11406658
    Abstract: The invention discloses a composition comprising glycyrrhizin, hyaluronic acid or a salt or a derivative thereof, and a viscosizing agent. The composition therefore finds advantageous application in all those cosmetic and therapeutic indications in which glycyrrhizin is used, since the composition according to the invention significantly improves the bioavailability thereof.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: August 9, 2022
    Assignee: ATG 20 S.R.L.
    Inventor: Marco Aldo Sanso′
  • Patent number: 11388910
    Abstract: This disclosure provides a high collagen composition prepared from a poultry broth and methods of making the same by filtration.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: July 19, 2022
    Assignee: INTERNATIONAL DEHYDRATED FOODS, INC.
    Inventors: Roger L. Dake, Jack C. Cappozzo, Stephanie Lynch
  • Patent number: 11383004
    Abstract: The present invention relates to methods for adhering tissue surfaces and materials and biomedical uses thereof. In particular the present invention relates to a method for adhering a first tissue surface to a second tissue surface in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on at least one of the tissue surfaces, and approximating the surfaces for a time sufficient for allowing the surfaces to adhere to each other. The present invention also relates to a method for adhering a material to a biological tissue in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on the surface of the material and/or the biological tissue and approximating the material and the biological tissue for a time sufficient for allowing the material and the biological tissue to adhere to each other.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: July 12, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS CITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS XIII PARIS-NORD, ÉCOLE SUPÉRIEUR DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE PARIS, SORBONNE UNIVERSITE
    Inventors: Ludwik Leibler, Anne Meddahi-Pellé, Didier Letourneur, Alba Marcellan-Parisot
  • Patent number: 11376274
    Abstract: A joint cavity injection preparation is provided. The active ingredient of the joint cavity injection preparation is deacetylated xanthan gum (XG). The deacetylated XG has a molecular weight of 500,000 to 20,000,000. The joint cavity injection preparation is prepared from deacetylated xanthan gum (XG), which has higher biocompatibility and safe wide-dosage range than existing joint cavity injection preparations prepared from XG.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: July 5, 2022
    Assignees: SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES, SHANDONG FREDA PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Peixue Ling, Fei Liu, Huarong Shao, Lei Chen, Zhiyun Zhang, Xiaoyuan Zhang, Qixin Chen, Guanying Han, Yanling Cheng, Jianqiang Zhang, Daizhou Zhang
  • Patent number: 11369627
    Abstract: The invention discloses a myrtle polysaccharide P1, the separation method thereof and the use in preparing hypolipidemic drugs therefor, wherein the P1 contains 6.74% of ribose, 1.73% of rhamnose, 60.06% of arabinose, 3.54% of xylose, 5.64% of mannose, 13.16% of glucose, and 9.13% of galactose. The experiment result shows that the myrtle polysaccharide P1 has a certain ability to bind cholate in vitro. Taking cholestyramine as a positive control and the binding rate of cholestyramine to each cholate as 100%, the relative binding rate of the myrtle polysaccharide P1 to sodium taurocholate, sodium glycocholate and sodium cholate was 25.28%, 44.56%, and 50.10%, respectively.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: June 28, 2022
    Assignee: South China Normal University School of Life Sciences
    Inventors: Ruqiang Huang, Jinghui Wang, Qian Wang, Linlin Gao, Jingwen Zhang
  • Patent number: 11344570
    Abstract: The present invention provides a pentosan polysulfate having a uronic acid content of 7.0 mass % to 15.0 mass % and an acetyl group content of 0 mass % to 2.0 mass %; a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable solvate of the pentosan polysulfate or of the pharmaceutically acceptable salt thereof. The pentosan polysulfate, the pharmaceutically acceptable salt thereof, or the pharmaceutically acceptable solvate of the pentosan polysulfate or of the pharmaceutically acceptable salt thereof are useful as an active ingredient of a medicament for preventing and/or treating a disease caused by abnormal enhancement of FGF-2 function, and as a pH buffer agent.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 31, 2022
    Assignee: OJI HOLDINGS CORPORATION
    Inventor: Suguru Ishikawa
  • Patent number: 11331335
    Abstract: Provided herein are methods and systems and related compositions comprising an effective amount of one or more zwitterionic polysaccharide possibly in combination with one or more antibiotics, for treatment and/or prevention of sepsis or a condition associated thereto in an individual.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: May 17, 2022
    Assignee: California Institute of Technology
    Inventors: Sarkis K. Mazmanian, June L. Round, Yue Shen
  • Patent number: 11318169
    Abstract: Compositions and preparations of fetal support tissue that prevent or reduce the proliferation and epithelial-mesenchymal transition (EMT) of epithelial cells, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or reducing the proliferation, cell migration, and EMT of epithelial cells in an individual in need thereof, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or treating proliferative vitreoretinopathy in an individual in need thereof.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: May 3, 2022
    Assignee: TISSUETECH, INC.
    Inventors: Scheffer Tseng, Ek Kia Tan, Hua He
  • Patent number: 11298517
    Abstract: A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: April 12, 2022
    Assignee: University of Maryland, College Park
    Inventors: Matthew Dowling, Srinivasa R. Raghavan
  • Patent number: 11297865
    Abstract: Methods of forming an ingredient for human consumption are provided herein. The methods may include isolating one or more soluble polysaccharides from a biomass, generating one or more oligosaccharides from the biomass, and combining the one or more isolated soluble polysaccharides with the generated oligosaccharides to form the ingredient. Methods of pretreating a biomass are also provided. The methods may include administering a physical pretreatment to a biomass, administering a gentle pretreatment to the physically pretreated biomass, and administering a strong pretreatment to the gently pretreated biomass. Ingredients for human consumption are also provided.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: April 12, 2022
    Assignee: CAMBRIDGE GLYCOSCIENCE LTD
    Inventors: Thomas J. Simmons, Jeremy Bartosiak-Jentys, Aleksandra Wlodek, Gustavo Valente
  • Patent number: 11299759
    Abstract: The present invention relates to a process for the enzymatic modification of a glycoprotein. The process comprises the step of contacting a glycoprotein comprising a glycan comprising a terminal GlcNAc-moiety, in the presence of glycosyltransferase that is, or is derived from, a ?-(1,4)-N-acetylgalactosaminyltransferase, with a non-natural sugar-derivative nucleotide. The non-natural sugar-derivative nucleotide is according to formula (3): wherein A is selected from the group consisting of —N3, —C(O)R3, —(CH2)iC?C—R4, —SH, —SC(O)R8, —SC(O)OR8, —SC(S)OR8, —F, —Cl, —Br —I, —OS(O)2R5, terminal C2-C24 alkenyl groups, C3-C5 cycloalkenyl groups, C4-C8 alkadienyl groups, terminal C3-C24 allenyl groups and amino groups.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: April 12, 2022
    Assignee: SYNAFFIX B.V.
    Inventors: Sander Sebastiaan Van Berkel, Remon Van Geel, Maria Antonia Wijdeven, Floris Louis Van Delft
  • Patent number: 11291678
    Abstract: New methods for treating and/or preventing cardiovascular disease including, for example, myocardial infarction and atherosclerosis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: April 5, 2022
    Assignees: GLYCOMIMETICS, INC, THE GENERAL HOSPITAL CORPORATION
    Inventors: John L Magnani, Matthias P Nahrendorf
  • Patent number: 11291645
    Abstract: A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: April 5, 2022
    Assignee: Vifor (International) AG
    Inventors: Peter Geisser, Erik Philipp, Walter Richle
  • Patent number: 11261264
    Abstract: An enzymatically produced soluble ?-glucan fiber composition is provided suitable for use as a digestion resistant fiber in food and feed applications. The soluble ?-glucan fiber composition can be blended with one or more additional food ingredients to produce fiber-containing compositions. Methods for the production and use of compositions comprising the soluble ?-glucan fiber are also provided.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: March 1, 2022
    Assignee: NUTRITION & BIOSCIENCES USA 4, INC.
    Inventors: Qiong Cheng, Robert DiCosimo, Arthur Ouwehand, Zheng You, Mark S. Payne, Jian Ping Lai, Kristin Ruebling-Jass, Steven Cary Rothman
  • Patent number: 11254792
    Abstract: A method for at least partial deacetylation of a biopolymer comprising acetyl groups, including: a1) providing a biopolymer including acetyl groups; a2) reacting the biopolymer including acetyl groups with hydroxylamine (NH2OH) or a salt thereof at a temperature of 100° C. or less for 2-200 hours to form an at least partially deacetylated biopolymer; and a3) recovering the at least partially deacetylated biopolymer.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: February 22, 2022
    Assignee: GALDERMA HOLDING SA
    Inventors: Johan Olsson, Craig Steven Harris
  • Patent number: 11248247
    Abstract: The present invention in the field of oligosaccharide production provides a method of producing oligosaccharides of useful lengths without producing substantial amounts of monosaccharides and disaccharides (illustrated by FIG. 1). There is provided a method for producing an ingredient suitable for incorporation into a foodstuff, cosmetic, or nutraceutical, said ingredient comprising one or more oligosaccharides, wherein the oligosaccharides are produced in an enzymatic reaction, said enzymatic reaction comprising the step of contacting, in a solution or suspension, a polysaccharide-cleaving enzyme and a polysaccharide-containing feedstock, wherein said enzymatic reaction produces substantially no monosaccharides or disaccharides.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: February 15, 2022
    Assignee: CAMBRIDGE GLYCOSCIENCE LTD
    Inventor: Thomas Simmons
  • Patent number: 11248063
    Abstract: A glycosaminoglycan derivative which is obtainable by a process that includes the steps of N-desulfation of from 25% to 100% of the N-sulfated residues of a glycosaminoglycan, and oxidation, by periodate at a pH of from 5.5 to 10.0, of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues, and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan, under conditions effective to convert adjacent diols and adjacent OH/NH2 to aldehydes. The process further includes reduction, by sodium borohydride, of said oxidized glycosaminoglycan, under conditions effective to convert said aldehydes to alcohols, where the glycosaminoglycan is heparin, low molecular weight heparin, heparan sulfate or fractions thereof.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: February 15, 2022
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 11234997
    Abstract: The invention relates to topical formulations comprising: a galactooligosaccharide; 0.01% to 10% w/w xylitol; and a pharmaceutically or cosmetically acceptable carrier. The invention also relates to use of the formulations, and methods for their preparation.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: February 1, 2022
    Inventors: Andrea Zanardi, Alessandra Cercaci, Ivan Montaldo
  • Patent number: 11229660
    Abstract: Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said gycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: January 25, 2022
    Assignee: Kaleido Biosciences, Inc.
    Inventors: Geoffrey A. von Maltzahn, Jared Silverman, Yvonne J. Yamanaka, John Miles Milwid, John M. Geremia
  • Patent number: 11219638
    Abstract: The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: January 11, 2022
    Assignees: INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER (IFREMER), UNIVERSITE DE NANTES, INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Sylvia Colliec-Jouault, Corinne Sinquin, Jacqueline Ratiskol, Dominique Heymann, Carmen Ruiz-Velasco, Julie Chesneau
  • Patent number: 11213572
    Abstract: Provided is a method of regenerating cartilage tissues by treatment with hyaluronan and proteoglycan link protein 1 (HAPLN1), and a composition for regenerating cartilage, the composition including HAPLN1 as an active ingredient. According to the present disclosure, the HAPLN1 protein may have cartilage formation-stimulating ability and articular cartilage regeneration ability, may increase an expression level of TGF-? receptor I of chondrocytes to increase a component ratio of cells having cartilage formation ability, and to induce regeneration of cartilage tissues. Accordingly, the HAPLN1 protein of the present disclosure, which is a novel composition regulating TGF-? signaling, may be usefully applied as a pharmaceutical composition for regenerating cartilage, a health food composition for regenerating cartilage, or a reagent composition for regenerating cartilage.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: January 4, 2022
    Assignee: HAPLNSCIENCE INC.
    Inventors: Dae Kyong Kim, Ji Min Jang
  • Patent number: 11198765
    Abstract: A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include ester crosslinks formed as byproducts during the amide crosslinking; and ii) subjecting the crosslinked glycosaminoglycans to alkaline treatment to hydrolyze ester crosslinks formed as byproducts during the amide crosslinking.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: December 14, 2021
    Assignee: GALDERMA HOLDING SA
    Inventors: Johan Olsson, Hotan Mojarradi
  • Patent number: 11191870
    Abstract: The present invention discloses polyglycol epoxide crosslinked sodium hyaluronate gel for injection and a preparation method thereof. A polyglycol epoxide is a compound with single molecular weight preferably; a plurality of ether bonds are present in the molecule of the polyglycol epoxide, the water solubility is good, and thus, the polyglycol epoxide is more easily subjected to a crosslinking reaction with polysaccharides; and meanwhile, polyglycol is relatively easy in adjustment of the number of repeating units and relatively easy in control of length, and thus, the sodium hyaluronate gel prepared by taking the polyglycol epoxide as a crosslinker is relatively easy in regulation and control of properties. The crosslinked sodium hyaluronate gel is low in toxicity, little in residual, small in squeezing and pushing force, good in shaping performance, good in enzyme resistance and long in in-vivo retention time. The present invention further discloses a mild crosslinker deactivation technology.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: December 7, 2021
    Assignee: JENKEM TECHNOLOGY CO., LTD.
    Inventors: Zhen Wei, Meina Lin, Xuan Zhao
  • Patent number: 11160746
    Abstract: An improved hair and scalp treatment composition comprising a hair care product wherein the improvement comprises reducing the comedogenicity thereof by excluding therefrom comedogenic elements having a Fulton scale grade greater than 2.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: November 2, 2021
    Assignee: CLARITY COSMETICS INC.
    Inventors: Iris Rubin, Gregory Maged, John Garruto, Bethany McCarver
  • Patent number: 11154568
    Abstract: The present invention relates to a composition for relieving a hangover or a composition for preventing, alleviating or treating alcoholic liver disease, comprising a ?-glucan as an active ingredient.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: October 26, 2021
    Assignee: QUEGEN BIOTECH CO., LTD.
    Inventors: Jong Dae Lee, Sung Hong Kim, Young Kyun Kim, Je Kyoung Kim, Yong Man Jang, Min Ji Kim, Eun Ji Park, Chul Su Yang
  • Patent number: 11154481
    Abstract: An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G? of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: October 26, 2021
    Assignee: Q-MED AB
    Inventors: Åsa Wiebensjö, Katarina Edsman
  • Patent number: 11154436
    Abstract: Disclosed is an absorbent article with biocompostable properties, such as a feminine hygiene pad. Particularly, the present invention is directed to an absorbent sanitary article with a high degree of biocompostability. The sanitary article comprises, in one embodiment, at least a top layer, a back layer, and absorbent core, wherein the absorbent core includes a superabsorbent polymer, and wherein at least the superabsorbent polymer is biocompostable. The absorbent article exhibits improved biocompostable properties and performance comparable to non-biodegradable absorbent articles which include non-biodegradable superabsorbent polymers.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: October 26, 2021
    Assignee: TETHIS, INC.
    Inventors: Ryan Nicholas Chan, Gordon Sidney Cox, Hailey Katherine Davis, Vladimiro Nettel
  • Patent number: 11123321
    Abstract: A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: September 21, 2021
    Assignee: VIFOR (INTERNATIONAL) AG
    Inventors: Peter Geisser, Erik Philipp, Walter Richie
  • Patent number: 11123455
    Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: September 21, 2021
    Assignees: CG Bio Co., Ltd., DNCompany, Daewoong Pharmaceutical Co., Ltd.
    Inventors: Ji Sun Lee, Su Hyun Jung, Hak Su Jang, Jung Eun Choo, Hye Young Jung
  • Patent number: 11116788
    Abstract: Disclosed is a composition for intravaginal and/or for internal mucosal application, comprising an effective amount of a sulfated polysaccharide, one or more of a natural quaternary polymer, a quaternary molecular compound, a metalloproteinase inhibitor, one or more anti-inflammatory agent, an acid pH control buffering system or any combination thereof, and a pharmaceutically acceptable carrier. Further disclosed is a method of treating or alleviating vaginal infection, vaginal dryness, vaginal or vulvo vaginal atrophy, vaginal itching, dyspareunia, vaginal or vulvar pain, vaginal or perivaginal inflammation or for promoting vaginal or wound healing, vaginal atrophy/dryness caused by radiotherapy, chemotherapy and/or hormonal treatment and decreased vaginal boundary lubrication or a disease or condition associated therewith or of improving vaginal boundary lubrication.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: September 14, 2021
    Assignee: ALGAMED THERAPEUTICS (A.M.T) LTD
    Inventor: Ronnie Klein
  • Patent number: 11116779
    Abstract: Disclosed are methods of modulating and/or decreasing serum corticosterone levels in an individual affected by stress. Further disclosed are methods of modulating the hypothalamic pituitary adrenal response in an individual. The methods include administration of 2-fucosyl-lactose to an individual.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: September 14, 2021
    Assignee: ABBOTT LABORATORIES
    Inventors: Enrique Vazquez Hernandez, Ricardo Rueda Cabrera, Rachael Buck, Maria Ramirez Gonzalez
  • Patent number: 11110117
    Abstract: Disclosed is a skin preparation composition for external use containing complex hyaluronic acid as an active ingredient, and specifically relates to a skin preparation composition for external use that contains hyaluronic acid, sodium hyaluronate, and hydrolyzed hyaluronic acid as active ingredients, and are excellent in an active oxygen scavenging effect, a wrinkle improvement effect, a moisturizing effect, a skin irritation relief effect, an acne prevention effect, an atopy improvement effect, and an anti-inflammatory effect, an hair damage prevention effect, and a hair loss prevention and hair growth effect.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: September 7, 2021
    Assignees: J2KBIO CO., LTD., COSMECCA KOREA CO., LTD.
    Inventors: Jae Soeb Lee, Jun Tae Bae, Seok Jong Kim, Young Kwon Cha, Hang Eui Cho, Ju Tae Jeong, Kyeong Seok So
  • Patent number: 11104747
    Abstract: Compositions are disclosed herein comprising a graft copolymer having (i) a backbone comprising dextran with a molecular weight of at least about 100000 Daltons, and poly alpha-1,3-glucan side chains comprising at least about 95% alpha-1,3-glucosidic linkages. Further disclosed are reactions for producing such graft copolymers, as well as their use in absorbent materials.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 31, 2021
    Assignee: NUTRITION & BIOSCIENCES USA 4, INC.
    Inventors: Natnael Behabtu, Samuel David Arthur
  • Patent number: 11096951
    Abstract: Provided is a prebiotic composition containing butyryl-fructooligosaccharide (B-FOS). B-FOS of the present invention facilitates selective growth of probiotics, thereby controlling intestinal microbes and contributing to physiological functions as an energy source of intestinal epithelial cells.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 24, 2021
    Assignee: BIFIDO CO., LTD.
    Inventors: Geun Eog Ji, Min Hee Um, Si Ni Kang, Myeong Soo Park, Bin Kwon
  • Patent number: 11091591
    Abstract: The invention relates to carbohydrate ligands and moieties, respectively, mimicking glycoepitopes comprised by glycosphingolipids of the nervous system, particularly glycoepitopes comprised by glycosphingolipids of the cerebroside, the globoside-, the ganglioside- and the sulfoglucuronyl paragloboside type, which are bound by anti-glycan antibodies associated with neurological diseases. The invention further relates to the use of these carbohydrate ligands/moieties, in diagnosis as well as for the treatment of neurological diseases associated with anti-glycan antibodies. In particular, the invention relates to compounds of formula (I) and (II) and to therapeutically acceptable polymers comprising a multitude of these compounds, including polymers with loading of one compound of formula (I) or (II) or combinations of several compounds of formula (I), and/or (II).
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: August 17, 2021
    Assignee: UNIVERSITÄT BASEL
    Inventors: Ruben Herrendorff, Beat Ernst, Andreas Steck, Hélène Pfister, Giulio Navarra
  • Patent number: 11077136
    Abstract: The present invention relates to a composition comprising hyaluronic acid, dermatan sulfate, at least one omega-3 fatty acid, and at least one nucleotide. It also relates to the new composition for use in the treatment or prevention of diseases, ailments, dysfunctions, or alterations of the skin, preferably atopic dermatitis. The composition may be in the form of a pharmaceutical composition, food supplement, functional food, or medical food.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: August 3, 2021
    Assignee: BIOIBERICA, S.A.U.
    Inventors: José Escaich Ferrer, Sergi Segarra López, Javier Córdoba Lucio, Jorge Flores García, Alfonso Velasco Franco
  • Patent number: 11077137
    Abstract: A method for treating diastolic heart failure is provided including identifying a subject having diastolic heart failure and administering a therapeutically effective amount of a galectin-3 inhibitor to the subject to at least partially alleviate a symptom of diastolic heart failure.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: August 3, 2021
    Assignee: Henry Ford Health System
    Inventor: Hani N. Sabbah